Table 1. The baseline characteristics in patients based on PD-L1 expression level.
| TPS 90–100% cohort | TPS 50–89% cohort | Total | |||
|---|---|---|---|---|---|
| Characteristics | (N = 50) | (N = 99) | (N = 149) | p value | |
| Age—yr | |||||
| Median (range) | 71 (47–82) | 71 (39–87) | 71 (39–87) | 0.72 | |
| Male—no. (%) | 40 (80.0) | 84 (84.9) | 124 (83.2) | 0.49 | |
| Smoking status—no. (%) | |||||
| Never | 4 (8.0) | 11 (11.1) | 15 (10.1) | 0.77 | |
| Current or former | 46 (92.0) | 88 (88.9) | 134 (89.9) | ||
| ECOG PS—no. (%) | |||||
| 0 | 13 (26.0) | 19 (19.2) | 32 (21.5) | 0.55 | |
| 1 | 26 (52.0) | 60 (60.6) | 86 (57.7) | ||
| 2 | 8 (16.0) | 16 (16.2) | 24 (16.1) | ||
| ≧3 | 3 (6.0) | 4 (4.0) | 7 (4.7) | ||
| Histological type—no. (%) | |||||
| Squamous | 9 (18.0) | 26 (26.3) | 35 (23.5) | 0.31 | |
| Non-Squamous | 41 (82.0) | 73 (73.7) | 114 (76.5) | ||
| EGFR mutation—no. (%) | |||||
| Positive | 2 (4.0) | 4 (4.0) | 6 (4.0) | 1.00 | |
| Negative | 42 (84.0) | 83 (83.8) | 125 (83.9) | ||
| Not evaluated | 6 (12.0) | 12 (12.1) | 18 (12.1) | ||
| EML4-ALK translocation—no. (%) | |||||
| Positive | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1.00 | |
| Negative | 43 (86.0) | 85 (85.9) | 128 (85.9) | ||
| Not evaluated | 7 (14.0) | 14 (14.1) | 21 (14.1) | ||
| Stage—no. (%) | |||||
| III | 9 (18.0) | 21 (21.2) | 30 (20.1) | 0.55 | |
| IV | 37 (74.0) | 65 (65.7) | 102 (68.5) | ||
| Recurrence | 4 (8.0) | 13 (13.1) | 17 (11.4) | ||
Categorical variables are presented as number (percentage), and continuous variables are presented as median and range. Categorical variables were compared by Fisher's exact test, and continuous variables were compared by the Wilcoxon rank sum test for two-group comparisons. PD-L1 = programmed death ligand-1, TPS = tumor proportion score, ECOG PS = Eastern Cooperative Oncology Group performance status, EGFR = epidermal growth factor receptor, EML4-ALK = echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase.